BioWorld

Feb. 15, 2007

Halozyme Getting Up To $65M From Expanded Baxter Alliance

Halozyme Therapeutics Inc. significantly expanded its relationships with Baxter Healthcare Corp., continuing momentum at the company that gained full steam two months ago. (BioWorld Today) Read More

Record Genzyme Revenues Clipped By AnorMED Buyout

Planning Pivotal MyoCell Trial, Bioheart Files For $35M IPO

Aging U.S. Population Is Fertile Ground For New Therapies

Current Orthopedic Strategies Complemented By Gene Therapy

GW Partners Sativex With Otsuka In Potential $273M Deal

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld Asia

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...